Department of Head and Neck/Plastic and Reconstructive Surgery, Roswell Park Cancer Institute, Buffalo, New York, USA.
Otolaryngol Head Neck Surg. 2014 Feb;150(2):237-44. doi: 10.1177/0194599813512783. Epub 2013 Nov 19.
Single-modality treatment, either with organ preservation surgery (OPS) or definitive radiation (RT), is the treatment of choice for patients with early supraglottic squamous cell carcinoma (SGC). However, studies comparing the effectiveness of these 2 techniques are lacking. This study compares the survival outcomes in early SGC patients treated with OPS versus RT.
Secondary data analysis.
Surveillance, Epidemiology and End Results database.
This study included adult patients with early-stage (T1N0, T2N0) SGC undergoing single-modality treatment with either OPS (with or without neck dissection [ND]) or RT between 1988 and 2008. Survival analysis was used to compare the overall survival (OS) and disease-specific survival (DSS) between patients treated with OPS+ND, OPS alone, and RT.
A total of 2631 T1/T2 N0 SGC patients were identified, of whom 167 (6%) were treated with OPS+ND, 186 (7%) with OPS only, and 2278 patients (87%) with definitive RT only. In stage I (T1N0) SGC patients, a significantly better 5-year DSS was noted for both OPS+ND (81% vs 68%, hazard ratio [HR] = 0.61, P = .03) and OPS only (82% vs 68%, HR = 0.70, P = .05) when compared with definitive RT. For stage II (T2N0) patients, only OPS+ND resulted in a significantly better 5-year DSS (86% vs 60%, HR = 0.31, P < .001) when compared with patients treated with RT.
Patients with early SGC who underwent OPS+ND had better OS and DSS than patients undergoing RT alone. OPS+ND may be considered a viable and preferred treatment option in these patients.
对于早期声门上鳞状细胞癌(SGC)患者,单一模式治疗,无论是器官保留手术(OPS)还是根治性放疗(RT),都是首选治疗方法。然而,缺乏比较这两种技术有效性的研究。本研究比较了接受 OPS 与 RT 治疗的早期 SGC 患者的生存结果。
二次数据分析。
监测、流行病学和最终结果数据库。
本研究纳入了 1988 年至 2008 年间接受单一模式治疗的 T1N0、T2N0 期早期 SGC 成年患者,治疗方法包括 OPS(伴或不伴颈部清扫术[ND])或 RT。生存分析用于比较 OPS+ND、OPS 单药治疗和 RT 治疗患者的总生存(OS)和疾病特异性生存(DSS)。
共纳入 2631 例 T1/T2 N0 SGC 患者,其中 167 例(6%)接受 OPS+ND 治疗,186 例(7%)接受 OPS 单药治疗,2278 例(87%)接受根治性 RT 治疗。在 I 期(T1N0)SGC 患者中,OPS+ND(81% vs 68%,风险比[HR] = 0.61,P =.03)和 OPS 单药(82% vs 68%,HR = 0.70,P =.05)治疗的 5 年 DSS 明显优于 RT。对于 II 期(T2N0)患者,只有 OPS+ND 治疗的患者 5 年 DSS 明显优于接受 RT 治疗的患者(86% vs 60%,HR = 0.31,P <.001)。
接受 OPS+ND 的早期 SGC 患者的 OS 和 DSS 优于单独接受 RT 的患者。在这些患者中,OPS+ND 可能是一种可行且首选的治疗选择。